false 0000875045 0000875045 2022-06-15 2022-06-15





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2022



Biogen Inc.

(Exact name of registrant as specified in its charter)




Delaware   0-19311   33-0112644

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)

Registrant’s telephone number, including area code: (617) 679-2000

Not Applicable

(Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.0005 par value   BIIB   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”). His last day at the Company will be June 30, 2022.


Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 15, 2022, the Company held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the Annual Meeting are as follows:



Stockholders elected eleven nominees to the Board of Directors to serve for a one-year term extending until the 2023 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:



   Votes For      Votes Against      Abstentions      Broker Non-Votes  

Alexander J. Denner

     82,710,582        32,524,166        664,096        10,427,787  

Caroline D. Dorsa

     85,668,149        30,030,982        199,713        10,427,787  

Maria C. Freire

     97,086,534        18,535,399        276,911        10,427,787  

William A. Hawkins

     97,324,728        18,022,577        551,539        10,427,787  

William D. Jones

     94,369,405        21,054,650        474,789        10,427,787  

Jesus B. Mantas

     95,166,348        20,524,662        207,834        10,427,787  

Richard C. Mulligan

     77,425,358        38,265,020        208,466        10,427,787  

Stelios Papadopoulos

     84,568,511        30,032,987        1,297,346        10,427,787  

Eric K. Rowinsky

     70,055,541        45,638,693        204,610        10,427,787  

Stephen A. Sherwin

     93,163,597        22,472,670        262,577        10,427,787  

Michel Vounatsos

     96,731,803        18,993,619        173,422        10,427,787  



Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, with the votes cast as follows:


Votes For


Votes Against




Broker Non-Votes

123,821,993   2,300,275   204,363   —  



Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:


Votes For


Votes Against




Broker Non-Votes

60,099,277   55,305,837   493,730   10,427,787


Item 9.01

Financial Statements and Exhibits.




The exhibits listed below are furnished as part of this Current Report on Form 8-K.


Exhibit No.



104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Biogen Inc.

/s/ Wendell Taylor

  Wendell Taylor
  Assistant Secretary

Date: June 21, 2022